Larotrectinib sulfate - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for larotrectinib sulfate and what is the scope of patent protection?
Larotrectinib sulfate
is the generic ingredient in one branded drug marketed by Bayer Hlthcare and Bayer Healthcare, and is included in two NDAs. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Larotrectinib sulfate has one hundred and ninety-four patent family members in forty-eight countries.
Two suppliers are listed for this compound.
Summary for larotrectinib sulfate
International Patents: | 194 |
US Patents: | 16 |
Tradenames: | 1 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 36 |
Clinical Trials: | 4 |
Patent Applications: | 132 |
DailyMed Link: | larotrectinib sulfate at DailyMed |
Recent Clinical Trials for larotrectinib sulfate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
M.D. Anderson Cancer Center | Phase 2 |
Children's Oncology Group | Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
Pharmacology for larotrectinib sulfate
Drug Class | Kinase Inhibitor |
Mechanism of Action | Tropomyosin Receptor Kinases Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for larotrectinib sulfate
US Patents and Regulatory Information for larotrectinib sulfate
International Patents for larotrectinib sulfate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Netherlands | 301033 | See Plans and Pricing | |
Canada | 2741313 | COMPOSES DE PYRAZOLO[1,5-A]PYRIMIDINE SUBSTITUES COMME INHIBITEURS DE LA TRK KINASE (SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS) | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 2017176744 | See Plans and Pricing | |
European Patent Office | 3439663 | MÉTHODES DE TRAITEMENT DE CANCERS PÉDIATRIQUES (METHODS OF TREATING PEDIATRIC CANCERS) | See Plans and Pricing |
Singapore | 10201900514R | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | See Plans and Pricing |
Australia | 2019275599 | Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for larotrectinib sulfate
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3106463 | 2020004 | Norway | See Plans and Pricing | PRODUCT NAME: LAROTREKTINIB OG/ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV, SAERLIG LAROTREKTINIBSULFAT INKLUDERT LAROTREKTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20191018 |
3106463 | 2090009-8 | Sweden | See Plans and Pricing | PRODUCT NAME: LAROTRECTINIB,OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY LAROTRECTINIB SULFATE INCLUDING LAROTRECTINIB HYDROGEN SULFATE; REG. NO/DATE: EU/1/19/1385 20190923 |
3106463 | 122020000012 | Germany | See Plans and Pricing | PRODUCT NAME: LAROTRECTINIB ODER ANDERE PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, EINSCHLIESSLICH LAROTRECTINIBSULFATE UMFASSEND LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190919 |
3106463 | PA2020504,C3106463 | Lithuania | See Plans and Pricing | PRODUCT NAME: LAROTREKTINIBAS IR (ARBA) FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, YPAC LAROTREKTINIBO SULFATAS, ISKAITANT LAROTREKTINIBO VANDENILIO SULFATA; REGISTRATION NO/DATE: EU/1/19/1385 20190919 |
3106463 | CA 2020 00013 | Denmark | See Plans and Pricing | PRODUCT NAME: LAROTRECTINIB OG/ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LAROTRECTINIBSULFAT, INKLUSIV LAROTRECTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20190923 |
3106463 | 722 | Finland | See Plans and Pricing | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.